Rodgers GM, Becker PS, Blinder M, Cella D, Chanan-Khan A, Cleeland C, et al. Cancer- and chemotherapy-induced Anemia. J Natl Compr Cancer Netw. 2012;10(5):628–53.
Article
Google Scholar
Harrison LB, Shasha D, White C, Ramdeen B. Radiotherapy-associated Anemia: the scope of the problem. Oncologist. 2000;5(suppl 2):1–7.
Article
PubMed
Google Scholar
Harrison L, Shasha D, Shiaova L, White C, Ramdeen B, Portenoy R. Prevalence of Anemia in Cancer Pateints undergoing radiation therapy. Semin Oncol. 2001;28(2):54–9.
Article
CAS
PubMed
Google Scholar
Harrison L, Shasha D, Homel P. Prevalence of anemia in cancer patients undergoing radiotherapy: prognostic significance and treatment. Oncology. 2002;63(Suppl 2):11–8.
Article
CAS
PubMed
Google Scholar
Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001;91:2214–21. https://doi.org/10.1002/(ISSN)1097-0142.
Article
CAS
PubMed
Google Scholar
Kumar P. Impact of Anemia in patients with head and neck Cancer. Oncologist. 2000;5(Suppl 2):13–8. https://doi.org/10.1634/theoncologist.5-suppl_2-13.
Article
PubMed
Google Scholar
Warde P, O’Sullivan B, Bristow RG, et al. T1/T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys. 1998;41:347–53.
Article
CAS
PubMed
Google Scholar
Rades D, Seidl D, Janssen S, Wollenberg B, Hakim SG, Schild SE. The effect of low hemoglobin levels on outcomes of radiotherapy following microscopically complete resection of locally advanced SCCHN: implications for the future. J Craniomaxillofac Surg. 2016;44(9):1441–4. https://doi.org/10.1016/j.jcms.2016.07.003 Hoff CM. Importance of hemoglobin concentration and its modification for the outcome of head and neck cancer patients treated with radiotherapy. Acta Oncol 2012;51:419–32.
Article
PubMed
Google Scholar
Gilreath JA, Stenehjem DD, Rodgers GM. Diagnosis and treatment of cancer-related anemia. Am J Hematol. 2014;89(2):203–12.
Article
PubMed
Google Scholar
Overgaard J, Hoff CM, Hansen HS, et al. DAHANCA 10 – effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group. Int J Radiat Oncol Biol Phys. 2018;127(1):12–9.
CAS
Google Scholar
Zimmermann M, Zouhair A, Azria D, et al. The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol. 2006;1:11. https://doi.org/10.1186/1748-717X-1-1.
Article
PubMed
PubMed Central
Google Scholar
Ray K, Ujvari B, Ramana V, Donald J. Cross-talk between EGFR and IL-6 drives oncogenic signaling and offers therapeutic opportunities in cancer. Cytokine Growth Factor Rev. 2018;41:18–27.
Article
CAS
PubMed
Google Scholar
Grellier N, Deray G, Yousfi A, Khodari W, Bouaita R. Belkacemi Y. Carence martiale fonctionnelle, inflammation et fatigue après radiothérapie Functional iron deficiency, inflammation and fatigue after radiotherapy. Bull Cancer. 2015;102(9):780–5. https://doi.org/10.1016/j.bulcan.2015.06.001 Epub 2015 Jul 31. PMID: 26235415. French.
Article
PubMed
Google Scholar
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78. https://doi.org/10.1056/NEJMoa053422 PMID: 16467544.
Article
CAS
PubMed
Google Scholar
Harari PM, Harris J, Kies MS, Myers JN, Jordan RC, Gillison ML, et al. Postoperative Chemoradiotherapy and Cetuximab for high-risk squamous cell carcinoma of the head and neck: radiation therapy oncology group RTOG-0234. J Clin Oncol. 2014;32:2486–95.
Article
CAS
PubMed
PubMed Central
Google Scholar
NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers, Version 3; 2021. Available at: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed June 21, 2021.
Petrelli F, Coinu A, Riboldi V, Borgonovo K, Ghilardi M, Cabiddu M, et al. Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies. Oral Oncol. 2014;50(11):1041–8. https://doi.org/10.1016/j.oraloncology.2014.08.005.
Article
CAS
PubMed
Google Scholar
Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014;32(27):2940–50.
Article
CAS
PubMed
PubMed Central
Google Scholar
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.
Article
CAS
PubMed
Google Scholar
Amin MB, Edge SB, Greene FL, et al., editors. AJCC Cancer staging manual. 8th ed. NewYork: Springer; 2017.
Google Scholar
El-Naggar AK, Westra WH. p16 expression as a surrogate marker for HPV-related oro-pharyngeal carcinoma: a guide for interpretative relevance and consistency. Head Neck. 2012;34:459–46.
Article
PubMed
Google Scholar
Schwartz, L.H.; Litière, S.; De Vries, E.; Ford, R.; Gwyther, S.; Mandrekar, S.; Shankar, L.; Bogaerts, J.; Chen, A.; Dancey, J.; et al. RECIST 1.1—update and clarification: from the RECIST committee. Eur J Dermatol Cancer 2016, 62, 132–137.
KDIGO. Summary of recommendation statements. Kidney Int. 2013;3 (Suppl):5.
Anemia: WHO, UNICEF, UNU. Iron deficiency anaemia: assessment, prevention, and control. A guide for programme managers. Geneva: World Health Organization; 2001. WHO/NHD/01.3
Google Scholar
Nien HH, Sturgis EM, Kies MS, El-Naggar AK, Morrison WH, Beadle BM, et al. Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus- associated oropharyngeal cancer. Head Neck. 2016;38(Suppl 1):E1554–61.
Article
PubMed
Google Scholar
Magrini SM, Buglione M, Corvo R, Pirtoli L, Paiar F, Ponticelli P, et al. Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck Cancer: a randomized phase II trial. J Clin Oncol. 2016;34(5):427–35.
Article
CAS
PubMed
Google Scholar
Hu MH, Wang LW, Lu HJ, Chu PY, Tai SK, Lee TL, et al. Cisplatin-based chemotherapy versus cetuximab in concurrent chemoradiotherapy for locally advanced head and neck cancer treatment. Biomed Res Int. 2014;2014:904341.
PubMed
PubMed Central
Google Scholar
Gebre-Medhin M, Brun E, Engstrom P, et al. ARTSCAN III: a randomized phase III study comparing chemoradiotherapy with cisplatin versus cetuximab in patients with locoregionally advanced head and neck squamous cell cancer. J Clin Oncol. 2021;39:38–47.
Article
CAS
PubMed
Google Scholar
Levy A, Blanchard P, Bellefqih S, Brahimi N, Guigay J, Janot F, et al. Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas. Strahlenther Onkol. 2014;190(9):823–31.
Article
PubMed
Google Scholar
Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol. 2013;31(7):853–9.
Article
CAS
PubMed
Google Scholar
Dornoff N, Weiss C, Rodel F, Wagenblast J, Ghanaati S, Atefeh N, et al. Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck. Strahlenther Onkol. 2015;191(8):656–64.
Article
PubMed
Google Scholar
Wichmann G, Cedra S, Schlegel D, Kolb M, Wiegand S, Boehm A, et al. Cilengitide and Cetuximab reduce cytokine production and Colony formation of head and neck squamous cell carcinoma cells ex vivo. Anticancer Res. 2017;37:521–7.
Article
CAS
PubMed
Google Scholar
Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393(10166):40–50.
Article
CAS
PubMed
Google Scholar
Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De- ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019;393(10166):51–60.
Article
CAS
PubMed
PubMed Central
Google Scholar